BCL2L1 and acute lymphoblastic leukemia: AZD4320, a dual BCL-2 and BCL-XL inhibitor, and AZD5991, which targets MCL-1, induce cell death in acute lymphoblastic leukemia cells when combined (Menendez et al. 2022).